GENE ONLINE|News &
BridgeBio’s New Heart Medication Sees Strong Early Demand After Approval
BridgeBio’s newly approved heart medication is exceeding initial projections, signaling robust market interest in the company’s first commercially available product. Following its recent approval, the drug has demonstrated stronger-than-anticipated demand, according to the company. This marks a significant step for BridgeBio as it launches its first major product and gauges its reception in the pharmaceutical market.
Newsflash | Powered by GeneOnline AI
Date: April 29, 2025
Related posts:
AXS25 Summit: Error-Proof Logistics, Value-Based Access, and Coordinated Reimbursement Needed for Expanding Cell and Gene Therapy Pipeline.
COVID-19 Infection Linked to Potential Kidney, GI, and Cardiovascular Issues in Children
Trump Administration Order Targets Medical School Accreditation Standards
Repetitive Tasks Linked to Reduced mPFC Activity, Increased Putamen Engagement in fMRI Study
LATEST
Boehringer Ingelheim and Tempus AI Partner in Multi-Year Collaboration to Enhance Oncology Drug Development
2025-05-15
Study: Aligning U.S. Drug Prices with Europe Could Reduce American Life Expectancy by Six Months
2025-05-15
Tribal Leaders Warn Senators: Federal Health Funding Cuts Threaten Native American Health.
2025-05-14
